BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 73215)

  • 1. Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate.
    Teger-Nilsson AC; Friberger P; Gyzander E
    Scand J Clin Lab Invest; 1977 Sep; 37(5):403-9. PubMed ID: 73215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The measurement of human plasma antiplasmin activity by radial diffusion assay.
    Andes WA
    Thromb Haemost; 1978 Apr; 39(2):437-49. PubMed ID: 79230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo.
    Levi M; Roem D; Kamp AM; de Boer JP; Hack CE; ten Cate JW
    Thromb Haemost; 1993 Feb; 69(2):141-6. PubMed ID: 7681223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmin inactivation in plasma.
    Haselager EM; Goote TM; Vreeken J
    Thromb Haemost; 1976 Jun; 35(3):643-50. PubMed ID: 62411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of the inhibition of plasmin in acidified human plasma.
    Lijnen HR; Maes M; Castel M; Samama M; Collen D
    Thromb Haemost; 1982 Dec; 48(3):257-9. PubMed ID: 6219470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha 2-antiplasmin Enschede is not an inhibitor, but a substrate, of plasmin.
    Rijken DC; Groeneveld E; Kluft C; Nieuwenhuis HK
    Biochem J; 1988 Oct; 255(2):609-15. PubMed ID: 2974279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assay of functional plasminogen in rat plasma applicable to experimental studies of thrombolysis.
    Bangert K; Thorsen S
    Thromb Haemost; 2000 Aug; 84(2):299-306. PubMed ID: 10959704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin-alpha 2-antiplasmin complex in human plasma--application to the detection of in vivo activation of the fibrinolytic system.
    Holvoet P; de Boer A; Verstreken M; Collen D
    Thromb Haemost; 1986 Oct; 56(2):124-7. PubMed ID: 2433784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin.
    Kramer MD; Reinartz J
    J Clin Invest; 1993 Aug; 92(2):978-83. PubMed ID: 7688770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The inhibitory effect of plasma inhibitor on plasmin activated with streptokinase or urokinase.
    Sumi H; Takada Y; Takada A
    Nihon Seirigaku Zasshi; 1977; 39(5):112-4. PubMed ID: 72149
    [No Abstract]   [Full Text] [Related]  

  • 12. Antifibrinolytic activities of alpha-N-acetyl-L-lysine methyl ester, epsilon-aminocaproic acid, and tranexamic acid. Importance of kringle interactions and active site inhibition.
    Anonick PK; Vasudevan J; Gonias SL
    Arterioscler Thromb; 1992 Jun; 12(6):708-16. PubMed ID: 1375508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control of coagulation and fibrinolysis by plasma proteinase inhibitors.
    Travis J; Salvesen G
    Behring Inst Mitt; 1983 Aug; (73):56-65. PubMed ID: 6206838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short peptides containing L-lysine and epsilon-aminocaproic acid as potential plasmin inhibitors.
    Purwin M; Bruzgo I; Markowska A; Midura-Nowaczek K
    Pharmazie; 2009 Nov; 64(11):765-7. PubMed ID: 20099524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of plasmin, miniplasmin, and streptokinase-plasmin complex by alpha 2-antiplasmin, alpha 2-macroglobulin, and antithrombin III in the presence of heparin.
    Anonick PK; Wolf B; Gonias SL
    Thromb Res; 1990 Aug; 59(3):449-62. PubMed ID: 1700488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic study of the effect of heparin on the amidase activity of trypsin, plasmin and urokinase.
    Yomtova VM; Stambolieva NA; Blagoev BM
    Thromb Haemost; 1983 Jun; 49(3):199-203. PubMed ID: 6224310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of a latex agglutination assay method for the determination of plasmin/alpha 2 plasmin inhibitor complex].
    Murakami F; Iijima K; Nakamura K; Ikawa S
    Rinsho Byori; 1994 Jun; 42(6):643-7. PubMed ID: 8051804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The contribution of plasma protease inhibitors to antiplasmin activity in man.
    Crawford GP; Ogston D; Douglas AS
    Clin Sci Mol Med; 1976 Aug; 51(2):215-8. PubMed ID: 60190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood inhibitory capacity toward exogenous plasmin.
    Banbula A; Zimmerman TP; Novokhatny VV
    Blood Coagul Fibrinolysis; 2007 Apr; 18(3):241-6. PubMed ID: 17413760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the antiplasmin activity of human thrombospondin-1 in solution.
    Anonick PK; Yoo JK; Webb DJ; Gonias SL
    Biochem J; 1993 Feb; 289 ( Pt 3)(Pt 3):903-9. PubMed ID: 7679575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.